Innovative pharmaceutical development company ABION announced on the 18th that it will participate in the '2025 Biotech Showcase' held in San Francisco, USA, from January 13 to 15 next year (local time), and the 'Bio Partnering JPM Week' held until the 16th.
The 2025 Biotech Showcase and Bio Partnering are events held in conjunction with the JP Morgan Healthcare Conference (JPM Week). During the event, participants such as biotech companies and investors are supported to smoothly arrange virtual or face-to-face meetings.
The JP Morgan Healthcare Conference is the world's largest pharmaceutical, biotech, and healthcare event held annually in January. More than 9,000 attendees and over 1,200 investors from around the world gather in one place to share research achievements and technologies and discuss business cooperation, serving as a global networking platform.
Through this event, ABION plans to introduce new pipelines such as ABN202 (antibody-cytokine fusion protein platform technology) and ABN501 (Claudin-3 targeted antibody therapy), as well as major research and development achievements. Recently, the company accelerated the development of the first-in-class drug by applying for a change in the clinical phase 2 trial plan of Vabametkib (ABN401) to evaluate the safety and efficacy of combination therapy with lazertinib.
An ABION representative said, "This event will be an opportunity to showcase ABION's innovative technology to investors and key executives in the biopharma industry and to discover new networks," adding, "Numerous meetings with new partners and investors are scheduled." He emphasized, "We will continue networking with existing partners and devote ourselves to long-term development."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
